Business Wire

NASA Selects Blue Origin for Astronaut Mission to the Moon

19.5.2023 19:23:00 EEST | Business Wire | Press release

Share

NASA has awarded a NextSTEP-2 Appendix P Sustaining Lunar Development (SLD) contract to Blue Origin. Blue Origin’s National Team partners include Lockheed Martin, Draper, Boeing, Astrobotic, and Honeybee Robotics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005272/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

A rendering of Blue Origin’s Blue Moon lander that will return astronauts to the Moon as part of NASA’s Artemis program. (Photo: Blue Origin)

Under this contract, Blue Origin and its National Team partners will develop and fly both a lunar lander that can make a precision landing anywhere on the Moon’s surface and a cislunar transporter. These vehicles are powered by LOX-LH2. The high-specific impulse of LOX-LH2 provides a dramatic advantage for high-energy deep space missions. Nevertheless, lower performing but more easily storable propellants (such as hydrazine and nitrogen tetroxide as used on the Apollo lunar landers) have been favored for these missions because of the problematic boil-off of LOX-LH2 during their long mission timelines. Through this contract, we will move the state of the art forward by making high-performance LOX-LH2 a storable propellant combination. Under SLD, we will develop and fly solar-powered 20-degree Kelvin cryocoolers and the other technologies required to prevent LOX-LH2 boil-off. Future missions beyond the Moon, and enabling capabilities such as high-performance nuclear thermal propulsion, will benefit greatly from storable LH2. Blue Origin’s architecture also prepares for that future day when lunar ice can be used to manufacture LOX and LH2 propellants on the Moon.

Blue Origin and its partners are already at work and are excited to be on this journey with NASA.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

media@blueorigin.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Experian's New Documentary RECLAIM Shows How Financial Access and Innovation Are Creating Opportunity Around the World5.11.2026 17:00:00 EET | Press release

For years, Almir dreamed of meeting his granddaughter in the United States. But unresolved debt stood in the way. Thousands of miles away in Arizona, Elizabeth faced mounting medical expenses after a health crisis. In London, Rochelle worked to regain control of her finances while caring for family members. Their stories, and others like them, are at the heart of RECLAIM: Stories of Passion and Perseverance, a new documentary from global technology and data company Experian that explores how access to financial tools, technology and support can help people overcome obstacles and pursue new opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105341861/en/ Behind-the-scenes photo from the filming of RECLAIM: Stories of Passion and Perseverance, an Experian documentary. Brody Frye, who received care from The MetroHealth System in Cleveland, Ohio, is featured in the film’s story about healthcare innovation and the p

Saudi Fund for Development Signs Six Development Loan Agreements Worth Over USD 403 Million with Syria5.11.2026 16:32:00 EET | Press release

The Saudi Fund for Development (SFD) has signed six concessional development loan agreements worth more than USD 403 million with the Syrian Arab Republic, marking a significant step in supporting the country’s recovery through the rehabilitation of essential infrastructure, restoration of vital public services and improvement of living conditions for communities affected by years of conflict. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105350224/en/ HRH the Crown Prince and President of the Syrian Arab Republic Al-Sharaa witness signing of agreements (Photo: AETOSWire The agreements, signed under the directives of the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, reflect the Kingdom’s continued commitment to supporting Syria’s development priorities. The signing ceremony was witnessed by Hi

LPs Expect Private Markets Managers to Level Up in 2027: SS&C Intralinks Survey5.11.2026 16:00:00 EET | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the publication of the 2027 LP Survey. In association with Reuters Insights, SS&C Intralinks surveyed 400 professionals working in private markets, including 370 limited partners and allocators, to understand how the alternative investments market will change in the next 12 months.* “Alternatives once again delivered in 2026, and LPs are still committing capital, but their expectations of managers continue to rise,” said Ken Bisconti, general manager of SS&C Intralinks. “Technology and data capabilities now rank among the most important criteria for selecting managers, alongside investment strategy. Performance alone is no longer enough. For nearly one-third of allocators, a credible artificial intelligence (AI) strategy is now a prerequisite for allocating capital to a manager.” Key findings from the report include: Alternatives portfolios continue to outperform. 62% of respondents said their portfolios exceeded expectati

Hyperice Unveils Normatec Elite Heat Legs: Integrated Heat Meets Dynamic Air Compression in a New Fully Wireless Design5.11.2026 16:00:00 EET | Press release

Hyperice, a high-performance wellness brand, today announced the launch of Normatec Elite Heat Legs, the newest innovation in the award-winning Normatec line and the first Normatec product to incorporate heat directly into its line of dynamic air compression therapy. As the 2024 launch of Normatec Elite signified a transformative leap forward in recovery technology, Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105782891/en/ Normatec Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. “Innovation has always been at the forefront of everything we do,” said Jim Huether, CEO of Hyperice. “Heat and dynamic air compressio

European Commission expands license for Alfasigma’s Jyseleca ® (filgotinib) with approval of new indication, treatment of adults with axial spondylarthritis5.11.2026 16:00:00 EET | Press release

The information contained within this press release is for the purpose of scientific exchange. It is intended for scientific, financial and investor media only. Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Commission (EC) has approved an additional indication to Jyseleca® (filgotinib) 200 mg and 100 mg film-coated tablets, an oral once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. A submission for UK approval has been made to the Medicines and Healthcare products Regulatory Agency (MHRA) and is under review. The European Commission’s approval is based on data that support a favourable benefit-risk profile for filgotinib, including efficacy and safety fin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye